Abstract：Objective To analyze the effects of ursodeoxycholic acid (UDCA) on the mRNA expression of multidrug resistance protein 3 (MDR3) and farnesoid X receptor (FXR) in infants with cholestatic hepatitis. Methods Twenty-eight infants who were diagnosed with cholestatic hepatitis between July 2008 and July 2010 were included in the study. These patients received treatment with UDCA. The mRNA expression levels of MDR3 and FXR were measured by real-time quantitative RT-PCR with SYBR Green I, before and after treatment with UDCA. Results After treatment with UDCA, the infants with cholestatic hepatitis had significantly decreased serum levels of total bilirubin, direct bilirubin, alanine aminotransferase, and gamma-glutamyltransferase (P<0.05) and significantly increased mRNA expression of MDR3 (P<0.05). No significant change in mRNA expression of FXR was observed, however (P>0.05). Conclusions UDCA improves liver function indices in infants with cholestatic hepatitis, which may be related to up-regulated mRNA expression of MDR3.
TANG Qing,WANG Lin-Lin,SHAN Qing-Wen et al. Effects of ursodeoxycholic acid on mRNA expression of MDR3 and FXR in infants with cholestatic hepatitis[J]. CJCP, 2013, 15(9): 756-758.
Paumgartner G, Pusl T. Medical treatment of cholestatic liver disease[J]. Clin Liver Dis, 2008, 12(1): 53-80.
[2]
Fickert P, Zollner G, Fuchsbichler A, Stumptner C, Pojer C, Zenz R, et al. Effects of ursodeoxycholic and cholic acid feeding on hepatocellular transporter expression in mouse liver[J]. Gastroenterology, 2001, 121(1): 170-183.
[3]
Huang L, Zhao A, Lew JL, Zhang T, Hrywna Y, Thompson JR, et al. Farnesoid X receptor activates transcrip-tion of the phospholipid pump MDR3[J]. J Biol Chem, 2003, 278(51): 51085-51090.
[4]
Benchimol EI, Walsh CM, Ling SC. Early diagnosis of neonatal cholestatic jaundice: test at 2 weeks[J]. Can Fam Physician, 2009, 55(12): 1184-1192.
Rost D, Rudolph G, Kloeters-Plachky P, Stiehl A. Effect of high dose ursode-oxycholic acid on its biliary enrichment in primary sclerosing cholangitis[J]. Hepatology, 2004, 40(3): 693-698.
[7]
Lindor KD, Kowdley KV, Luketic VA, Harrison ME, McCashland T, Befeler AS, et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis[J]. Hepatology, 2009, 50(3): 808-814.
[8]
Marschall HU, Wagner M, Zollner G, Fickert P, Diczfalusy U, Gumhold J, et al. Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and urso-deoxycholic acid in humans[J]. Gastroenterology, 2005, 129(2): 476-485.
[9]
Poupon R. Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action[J]. Clin Res Hepatol Gastroentero, 2012, 36(3): 70015-70013.
[10]
Stedman C, Robertson G, Coulter S, Liddle C. Feed-forward regulation of bile acid detoxification by CYP3A4: studies in humanized transgenic mice[J]. J Biol Chem, 2004, 279(12): 11336-11343.
